Skip to main content

Table 4 Effectiveness, costs, transition probabilities, base case discount rate and variations in sensitivity analysis

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Parameters Base case Variation in sensitivity analysis Reference
Overall survival of first-line therapy (strategy 1) 17.6 15.8–19.3 Macedo et al. (2012) [7]
Overall survival of second-line therapy (strategy 1) 20.6 18.5–22.6 Tournigand et al. (2004) [12]
Overall survival of supportive care (strategy 1) 18 16.2–19.8 Van Cutsem et al. (2007) [18]
Overall survival of first-line therapy (strategy 2) 19.8 17.8–21.8 Macedo et al. (2012) [7]
Overall survival of second-line therapy (strategy 2) 20.6 18.5–22.6 Tournigand et al. (2004) [12]
Overall survival of supportive care (strategy 2) 18 16.2–19.8 Van Cutsem et al. (2007) [18]
Cost of first-line therapy (strategy 1) 8256.32 6636.06–9876.58 Assumed
Cost of second-line therapy (strategy 1) 12,984.00 11,600.7–14,367.3 Assumed
Cost of supportive care (strategy1) 5032.51 4529.26–5535.76 Assumed
Cost of first-line therapy (strategy 2) 30,805.48 20,664–40,946.96 Assumed
Cost of second-line therapy (strategy 2) 12,984.00 11,600.7–14,367.3 Assumed
Cost of supportive care (strategy2) 5032.51 4529.26–5535.76 Assumed
Probability of transition from first-line therapy to first-line therapy (strategy 1) 0.66 0.60–0.72 Assumed
Probability of transition from first-line therapy to second-line therapy (strategy 1) 0.2 0.18–0.22 Hurwitz et al.
(2013) [17]
Probability of transition from first-line therapy to supportive care (strategy 1) 0.08 0.07–0.09 Saltz et al. (2008) [4]
Probability of transition from first-line therapy to death (strategy 1) 0.06 0.04–0.08 Hurwitz et al. (2013) [17]
Probability of transition from second-line therapy to second-line therapy (strategy 1) 0.49 0.45–0.53 Tournigand et al. (2004) [12]
Probability of transition from second-line therapy to supportive care (strategy 1) 0.45 0.41–0.49 Tournigand et al. (2004) [12]
Probability of transition from second-line therapy to death (strategy 1) 0.06 0.04–0.08 Tournigand et al. (2004) [12]
Probability of transition from supportive care to supportive care (strategy 1) 0.75 0.68–0.82 Van Cutsem et al. (2007) [18]
Probability of transition from supportive care to death (strategy 1) 0.25 0.23–0.27 Van Cutsem et al. (2007) [18]
Probability of transition from first-line therapy to first-line therapy (strategy 1) 0.67 0.61–0.73 Assumido
Probability of transition from first-line therapy to second-line therapy (strategy 1) 0.12 0.10–0.14 Hurwitz et al. (2013) [17]
Probability of transition from first-line therapy to supportive care (strategy 1) 0.16 0.14–0.18 Saltz et al. (2008) [4]
Probability of transition from first-line therapy to death (strategy 1) 0.05 0.04–0.06 Hurwitz et al. (2013) [17]
Probability of transition from second-line therapy to second-line therapy (strategy 1) 0.49 0.45–0.53 Tournigand et al. (2004) [12]
Probability of transition from second-line therapy to supportive care (strategy 1) 0.45 0.41–0.49 Tournigand et al. (2004) [12]
Probability of transition from second-line therapy to death (strategy 1) 0.06 0.04–0.08 Tournigand et al. (2004) [12]
Probability of transition from supportive care to supportive care (strategy 1) 0.75 0.68–0.82 Van Cutsem et al. (2007) [18]
Probability of transition from supportive care to death (strategy 1) 0.25 0.23–0.27 Van Cutsem et al. (2007) [18]
Discount rate 5% 0–10% Brasil, 2014 [13]